Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Dose-escalation Study of the Safety, Tolerability and Ability of CMX001 to Prevent or Control Cytomegalovirus (CMV) Infection in R+ Hematopoietic Stem Cell Transplant Recipients

This study has been completed.
Sponsor:
Information provided by:
Chimerix
ClinicalTrials.gov Identifier:
NCT00942305
First received: July 17, 2009
Last updated: January 16, 2012
Last verified: January 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2012
  Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
No publications provided by Chimerix

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):